Introduction
Currently, we use the classification criteria for antiphospholipid syndrome (APS) formulated during the consensus conference in Sapporo and revised in Sydney [1] . Classification criteria for definite APS are met when at least one clinical criterion (thrombosis or pregnancy morbidity) and one laboratory criterion (lupus anticoagulant (LAC), anticardiolipin antibodies (aCL) or beta2-glycoprotein I antibodies (ab2GPI)) are present. Positive laboratory tests should be confirmed 12 weeks after the initial testing. Recommendations published in 2009 and 2014 by the Scientific Standardisation Subcommittee (SSC) on Lupus Anticoagulant/Phospholipid Antibodies for the detection of LAC and aCL/ab2GPI antibodies have proven useful working documents on how to perform the assays [2, 3] . In addition, since 2006 a huge number of publications on which laboratory tests to use have been published, addressing the sensitivity and specificity of aCL and ab2GPI, level for positivity, isotype, other antiphospholipid antibodies (aPL), etc. There is contrasting information in these studies, which may be confusing for the end user. This is a major concern of this Subcommittee, and therefore the past and present Chairs decided to summarize the consensus on laboratory criteria, with a focus on what has changed since 2006.
Clarification of the recommendations summarized in Table 1 Lupus anticoagulant LAC persists as a well-established thrombotic risk factor, illustrated in many studies and often based on the metaanalysis of Galli [4, 5] . However, in this meta-analysis no distinction was made between isolated LAC and LAC associated with positivity in ELISA tests. When isolated LAC only is considered, the risk of thrombosis is low [6] . For LAC we rely on a combination of two phospholipid (PL)-dependent clotting assays as no single test has sufficient sensitivity and specificity [2] . With all the disadvantages of LAC testing [7, 8] , the search for better-performing coagulation assays in LAC continues. Functional assays that can discriminate between thrombosis-related and nonthrombosis-related aPL have been described, including thrombin generation assays [9, 10] . Thrombin generation depends on the presence of negative phospholipid surfaces, and one single test may provide more accurate information than the multitude of clotting assays required in LAC testing today. However, these assays are not robust enough to use in routine testing yet. So, the multiple-step procedure, with screening, mixing and confirmation steps, is still applied [1, 2] . LAC testing in patients under treatment with anticoagulation therapy may cause erroneous results, but this is beyond the scope of this paper and will be addressed in a separate SSC recommendation.
Anticardiolipin and beta2-glycoprotein I antibodies
In the Sydney criteria ab2GPI was added as an extra laboratory criterion and not as a substitute for aCL. Consequently, we recommend performing all three tests (LAC, aCL and ab2GPI) to diagnose APS [1] [2] [3] .
Traditionally, aCL and ab2GPI are detected by ELISA [1] ; however, recently automated platforms with variations of the solid phase (e.g. magnetic microparticles and microspheres) and various detection systems (e.g. chemiluminescense, flow cytometry and multiplex systems) have been introduced into the market [11] [12] [13] [14] [15] [16] . Automated systems have the advantage that the working conditions are more harmonized, providing a strict protocol on how to perform the assay, which may reduce the inter-laboratory variation [17] . They perform aCL and ab2GPI IgG/IgM assays more rapidly and are less labor intensive, providing the four results at once, instead of running multiple ELISAs.
Although it is not specified in the Sydney criteria that aCL should be b2GPI dependent, it is mandatory to avoid detection of non-cofactor-related aCL associated with infections or several drugs [1, 3] . Specificity of aCL assays depends on the source and amount of b2GPI [18, 19] . After the discovery of b2GPI as the most important cofactor for aPL, the ab2GPI assay was thought to be more specific and more reliable for standardization. A debate started on the role of aCL, but soon it became clear that ab2GPI assays suffer from the same problems of standardization and that methodologically correct b2GPI-dependent aCL assays do have diagnostic value, with identical sensitivities and specificities to ab2GPI assays [16, 20] . Not surprisingly, because all these assays use b2GPI antigen, a high correlation is observed between aCL and ab2GPI levels [13, 16] .
A major problem is the high variability between the commercially available aCL and ab2GPI assays in classifying samples as positive or negative and in antibody level. In external quality control exercises and using human monoclonal antibodies with different reactivity towards b2GPI discriminating detection of open and closed confirmation of b2GPI, differences were demonstrated in commercially available ab2GPI IgG ELISA assays, as well as in automated systems [21] [22] [23] .
The role of IgM has been discussed based on a stronger association of IgG with thrombosis compared with IgM [4, 24] , whereas for pregnancy morbidity the role of IgM should be further established [19] . A more recent systematic review of the literature on the role of IgM aPL was not able to give a clear answer [25] . More significant IgG correlations with thrombosis were confirmed; however, significant associations for IgM were also found, but with corresponding IgG. Unavailability of paired results of IgG and IgM for each separate patient hampered the evaluation of added value of IgM and the question of how many APS patients would be missed upon omission of IgM could not be answered [25] . We advise continued measurement of IgG and IgM; moreover, the presence of aCL and ab2GPI of the same isotype reinforces the clinical probability of APS [26] . The significance of IgA aCL and ab2GPI remains controversial [1, 3] . Future studies are needed to investigate the role of IgA in APS-associated clinical events.
Lacking an international standard, we still have to report a level derived from the calibration curve, which can differ widely between systems [7] . Although useful for the clinician and making positive and negative results interchangeable between different systems, semiquantitative results (low-medium-high) are difficult to define. Each test result above the cut-off value calculated as higher than the 99th percentile, should be regarded as positive [3] . However, lower levels of antibodies are observed in certain clinical settings, especially pregnancy morbidity [27, 28] . The clinical relevance of aCL and/or ab2GPI results that are below the 99th percentile needs to be studied and better defined using standardized laboratory methods.
Antibody profiles
To characterize the patient's antibody profile, all three tests should be performed, preferentially in the same sample. Antibody profiles were already introduced into the Sydney criteria, categorizing patients into groups with one or more laboratory criteria (in any combination) present [1] . A modification of this categorization was described, taking into account the type and the number of positive tests [29] . Evidence has shown that patients with more than one positive test, and particularly those patients with triple positivity (LAC and aCL and ab2GPI; same isotype), show the strongest association with thrombotic and obstetric APS [30, 31] . Moreover, clinical studies confirm that triple positivity in APS patients and carriers indicates a high risk of recurrence of thrombosis or development of a first thrombosis, respectively [32, 33] . Double-positive patients (mostly LAC negative) are generally at lower risk. Probably, in these patients ab2GPI level is insufficient to induce LAC positivity [34] . Single-positive patients (LAC, aCL or ab2GPI) are less likely to develop aPL-related events [1] . However, in obstetric APS and in arterial thrombosis (myocardial infarction and stroke) being LAC positive, independent of the associated other aPL, was the main predictor for thrombotic events and adverse pregnancy outcome [35, 36] . Clinical studies should report results on patient populations with homogeneous aPL profiles.
In making antibody profiles, we should be aware of inter-assay and inter-laboratory variability and the performance characteristics of the assays: a sample assigned positive in one assay does not automatically test positive in an assay from a different manufacturer or in another laboratory [7, 22] . Agreement for triple positivity between systems needs to be further studied, but looks promising [37, 38] . Testing with other methods can be useful in patients with high clinical suspicion. Because interpretation of aPL results may be challenging, test results should always be related to clinical symptoms and an interaction between the laboratory and clinician is essential.
Other antiphospholipid antibodies
The b2GPI domain I antibodies (aD1), a subgroup of IgG ab2GPI, are strongly associated with thrombosis [39, 40] . So far, research assays have been applied to detect these antibodies, but recently a commercial chemiluminescence immunoassay assay (CIA) has become available to detect aD1. Several studies with the CIA aD1 assay confirmed high odds ratios for thrombosis and the role of aD1 in risk stratification [41] [42] [43] [44] . Correlating to the higher risk, aD1 IgG are mainly present in triple-positive patients, also showing higher levels [42, 43] . A limited number of studies have evaluated whether the aD1 are independent risk factors for thrombosis, and showed that aD1 had no added value to the current aPL panel [42, 45] . So far, aD1 measured by the only available commercial assay should be considered as a confirmation of the higher thrombotic risk, rather than a candidate for replacement of the ab2GPI. Recently it was shown, using the monoclonal antibodies that detect the percentage of exposure of epitope G40-R43 on domain I in full-length beta2GPI, that in these commercial aD1 assays, not all epitopes on domain I are exposed. However, we cannot exclude that other epitopes on domain I may play a role. Antibodies to other domains of b2GPI are not associated with thrombotic events [46] .
Antibodies to phosphatidylserine/prothrombin (aPS/ PT) have been investigated in addition to the current aPL panel in APS patients with favorable results, regarding their potential diagnostic value [47] . Mainly associated with LAC, their additional value in APS diagnosis needs to be confirmed [48] .
Repeat testing
Although triple-positive patients have a persistently abnormal antibody profile on follow-up testing after 12 weeks [49] , we still recommend re-testing for confirmation after 3 months. This was originally meant to avoid over-diagnosis by classification of transient positivity of antibodies as APS [1, 2] . However, reproducing the same test results as for the initial positive test after 3 months ensures the reliability of the positive test, which is important in the context of poor standardization and interferences with effect on the test result [7, 49] .
In conclusion, the joint efforts of independent organizations are contributing to an improved standardization of the assays and diagnosis of APS. The SSC on Lupus Anticoagulant/Phospholipid Antibodies continues to work on improvement of the detection of aPL. 
